Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ivan Castillo-Salazar

Ophthalmology Waco, TX Medical Doctor

NPI 1316155443 CMS profile 14525

7030 New Sanger Rd Ste 102, Waco, TX 76712

Open in the dashboard

General payments

$10,443

315 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ivan Castillo-Salazar of Waco, TX is reported in the CMS Open Payments database as having received $10,443 across 315 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,224 98
2024 General $2,130 70
2023 General $2,016 53
2022 General $1,116 38
2021 General $592 21
2020 General $424 17
2019 General $940 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ivan Castillo-Salazar
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Ivan Castillo-Salazar were reported at $3,224. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Ivan Castillo-Salazar Ophthalmology median Middle half National median
2019 $940 $258 $104–$655 $163
2020 $424 $126 $45–$321 $114
2021 $592 $205 $76–$534 $132
2022 $1,116 $266 $100–$678 $149
2023 $2,016 $308 $117–$745 $160
2024 $2,130 $340 $127–$846 $164
2025 $3,224 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Regeneron Healthcare Solutions, Inc. $2,620 75 payments
  2. Astellas Pharma US Inc $1,036 30 payments
  3. Apellis Pharmaceuticals, Inc. $986 31 payments
  4. Genentech USA, Inc. $803 27 payments
  5. Mallinckrodt Hospital Products Inc. $773 24 payments
  6. Alcon Vision LLC $656 4 payments
  7. Alimera Sciences, Inc. $622 15 payments
  8. ANI Pharmaceuticals, Inc. $543 17 payments
  9. AbbVie, Inc. $304 13 payments
  10. Bausch & Lomb, a division of Bausch Health US, LLC $269 13 payments
  11. Other $1,830 66 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,915 307 payments
  2. Education $253 5 payments
  3. Travel and Lodging $252 2 payments
  4. Entertainment $22 1 payment
Products named General payments · program years 2019–2025
  1. EYLEA HD $2,327 60 payments
  2. EYLEA $1,431 45 payments
  3. Izervay $955 27 payments
  4. Syfovre $933 29 payments
  5. ACTHAR $773 24 payments
  6. VABYSMO $698 23 payments
  7. ILUVIEN Ophthalmology $417 11 payments
  8. ILUVIEN treatment of diabetic macular edema in patients who have been previously treated with corticosteroid $408 13 payments
  9. Cimerli $358 12 payments
  10. OZURDEX $336 18 payments
  11. Other $2,015 80 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

905

Median for Ophthalmology: 891

Drug cost

$57,750

Median for Ophthalmology: $68,233

Branded share of claims

29.6%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Bromfenac Sodium Generic 83 $13,100
Prolensa Bromfenac Sodium Brand 27 $10,593
Brimonidine Tartrate-Timolol Brimonidine Tartrate/Timolol Brand 55 $8,611
Prednisolone Acetate Generic 136 $7,424
Combigan Brimonidine Tartrate/Timolol Brand 19 $6,723
Simbrinza Brinzolamide/Brimonidine Tart Brand 14 $2,644
Difluprednate Generic 13 $1,928
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 119 $1,665
Dorzolamide Hcl Generic 77 $1,258
Latanoprost Generic 132 $1,048

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 58 billing codes

Paid by Medicare

$6,453,876

Of which drugs: $5,351,718

Medicare patients

1,242

Average age 77

Services billed

66,044

730 women, 512 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 43%
Diabetes 39%
Ischemic heart disease 29%
Chronic kidney disease 25%
Depression 21%
Atrial fibrillation 20%
Heart failure 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, aflibercept, 1 mg J0178 Office 339 3,734 $2,450,864
Injection, aflibercept hd, 1 mg J0177 Office 166 3,969 $1,040,031
Injection, faricimab-svoa, 0.1 mg J2777 Office 78 37,143 $1,026,432
Injection, avacincaptad pegol, 0.1 mg J2782 Office 51 5,761 $499,101
Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg Q5128 Office 18 585 $110,009
Injection, triamcinolone acetonide (xipere), 1 mg J3299 Office 39 2,700 $102,629
Injection, dexamethasone, intravitreal implant, 0.1 mg J7312 Office 19 212 $33,849

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
EYLEA HD
  • Regeneron Healthcare Solutions, Inc. $572
$572 — 3,969
Izervay
  • Astellas Pharma US Inc $505
$505 — 5,761
ACTHAR
  • Mallinckrodt Hospital Products Inc. $178
$178 — —
Cimerli
  • Sandoz Inc. $114
  • Coherus Biosciences Inc. $59
$172 — 585
Syfovre
  • Apellis Pharmaceuticals, Inc. $172
$172 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

315 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record